NetScientific PLC PDS Appoints Ilian Iliev to the Board
14 Abril 2020 - 3:04AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
14 April 2020
NetScientific plc
("NetScientific" or the "Company")
PDS Biotechnology Appoints Dr. Ilian Iliev to Board of
Directors
London, UK - 14 April 2020 - NetScientific plc (AIM: NSCI), the
transatlantic healthcare IP commercialisation Group, today
announces that its portfolio company PDS Biotechnology Corporation
("PDS") (Nasdaq: PDSB) announced on 9(th) April 2020 the
appointment of Dr. Ilian Iliev to its Board of Directors.
Below is the full announcement made today by PDS
Biotechnology
# # #
PDS Biotechnology Appoints Dr. Ilian Iliev to Board of
Directors
PRINCETON, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- PDS
Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a
clinical-stage immuno-oncology company developing multiple
therapies based on T-cell activating technology called Versamune(R)
today announced that it has appointed Ilian Iliev, Ph.D. to its
Board of Directors.
"We are very pleased to welcome Dr. Iliev to the Board of
Directors. He brings a wealth of experience to PDS Biotech as a
recognized entrepreneur and venture capitalist across multiple
industries, including healthcare," commented Steve Glover, Chairman
of the Board of PDS Biotech. "Together, we will help guide PDS
Biotech through its near and long-term milestones as we advance our
programs in infectious disease and immuno-oncology with leading
research institutions and pharmaceutical companies."
Currently, Dr. Iliev is a Managing Director of EMV Capital, a
London-based investor in B2B companies in the healthcare,
transportation, energy and technology sectors. Previously he
founded CambridgeIP, a boutique consultancy focused on IP
commercialization based out of Cambridge, UK and working with
clients in healthcare, energy and other sectors. Dr. Iliev is a
Board Member of NetScientific PLC, a transatlantic healthcare IP
commercialization group that funds and develops companies that are
working to significantly improve the health and well-being of
people with chronic diseases. He also serves on the Board of
Directors of Sofant Technologies, Pointgrab, Q-Bot, Glycotest,
Vortex Biosciences and Wanda Health.
Dr. Iliev holds a Ph.D. from Cambridge University's Judge
Business School, focused on Venture Capital business models in
emerging economies. He also received a Master of Commerce in
Economics, and Bachelor of Arts in Politics, Economics and
International Relations from the University of Witwatersrand. He
has published widely on entrepreneurship, venture capital, and
market trends in healthcare and energy and is an Associate Fellow
at the Royal Institute of International Affairs
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company with a
growing pipeline of infectious disease vaccines and cancer
immunotherapy based on the Company's proprietary Versamune(R)
T-cell activating technology platform. The Versamune(R) platform
effectively delivers disease-specific antigens for in vivo uptake
and processing, while also activating a critical immunological
pathway, the type 1 interferon pathway, thus resulting in the
production of both neutralizing antibodies and potent
disease-specific killer T-cells. Using Versamune(R), PDS Biotech is
engineering therapies designed to better recognize disease cells to
effectively attack and destroy them. PDS Biotech's pipeline
combines the Versamune(R) technology with disease-specific antigens
across several therapeutic areas. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
Ian Postlethwaite, CEO/CFO
WHIreland (NOMAD, Financial Adviser Tel: +44 (0)20 7220 1666
and Broker)
Chris Fielding / Darshan Patel
MO PR ADVISORY (Press Contact) Tel: +44 (0)78 7644 4977
Mo Noonan
About NetScientific
NetScientific PLC is a transatlantic healthcare IP
commercialisation Group focused on technologies and companies that
have the potential to treat chronic disease and significantly
improve the health and well-being of people.
For more information, please visit the website at www.NetScientific.net
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFLFFASEIVLII
(END) Dow Jones Newswires
April 14, 2020 02:04 ET (06:04 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024